Rubius Therapeutics to Participate in Jefferies Virtual Healthcare Conference
May 20 2021 - 8:30AM
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage
biopharmaceutical company that is genetically engineering red blood
cells to create an entirely new class of cellular medicines called
Red Cell Therapeutics™, today announced that Pablo J. Cagnoni,
M.D., president and chief executive officer, will participate in a
fireside chat at the Jefferies Virtual Healthcare Conference on
June 2, 2021, at 4:00 p.m. EDT.
A live audio webcast will be available within the
Investors & Media section of the Rubius Therapeutics website.
An archived replay will be accessible for 90 days following the
event.
About Rubius TherapeuticsRubius
Therapeutics is a clinical-stage biopharmaceutical company
developing a new class of medicines called Red Cell Therapeutics™.
The Company’s proprietary RED PLATFORM® was designed to genetically
engineer and culture Red Cell Therapeutics™ that are selective,
potent and off-the-shelf allogeneic cellular therapies for the
potential treatment of several diseases across multiple therapeutic
areas. Rubius’ initial focus is to advance RCT™ product candidates
for the treatment of cancer and autoimmune diseases by leveraging
two distinct therapeutic modalities — potent cell-cell interaction
and tolerance induction. Rubius Therapeutics was named among
the 2020 Top Places to Work in Massachusetts by the Boston Globe,
and its manufacturing site was recently named 2021 Best
Places to Work in Rhode Island by Providence Business News.
For more information, visit www.rubiustx.com, follow us on Twitter
or LinkedIn or like us on Facebook.
Contacts:
InvestorsElhan Webb, CFA, VP Investor
Relationselhan.webb@rubiustx.com
Media Marissa Hanify, Director, Corporate
Communicationsmarissa.hanify@rubiustx.com
Dan Budwick, 1AB+1 (973) 271-6085dan@1abmedia.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jul 2023 to Jul 2024